Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M79,629Revenue (TTM) $M9,687Net Margin (%)17.4Altman Z-Score3.7
Enterprise Value $M88,190EPS (TTM) $2.1Operating Margin %24.8Piotroski F-Score5
P/E(ttm)49.7Beneish M-Score-2.3Pre-tax Margin (%)21.9Higher ROA y-yN
Price/Book15.710-y EBITDA Growth Rate %--Quick Ratio4.3Cash flow > EarningsY
Price/Sales8.65-y EBITDA Growth Rate %23.1Current Ratio4.6Lower Leverage y-yN
Price/Free Cash Flow36.4y-y EBITDA Growth Rate %-11.4ROA % (ttm)7.3Higher Current Ratio y-yN
Dividend Yield %--PEG2.1ROE % (ttm)28.6Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M775ROIC % (ttm)18.7Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGJulian Robertson 2016-03-31 Buy 5.74%$96.69 - $119.76
($103.22)
$ 101.02-2%New holding228,840
CELGJoel Greenblatt 2016-03-31 Buy 0.08%$96.69 - $119.76
($103.22)
$ 101.02-2%New holding68,917
CELGKen Fisher 2016-03-31 Reduce-0.01%$96.69 - $119.76
($103.22)
$ 101.02-2%Reduce -19.27%198,160
CELGMario Gabelli 2016-03-31 Reduce$96.69 - $119.76
($103.22)
$ 101.02-2%Reduce -7.26%27,144
CELGJoel Greenblatt 2015-12-31 Sold Out -0.01%$106.55 - $127.2
($115.78)
$ 101.02-13%Sold Out0
CELGKen Fisher 2015-12-31 Add$106.55 - $127.2
($115.74)
$ 101.02-13%Add 0.37%245,460
CELGMario Gabelli 2015-12-31 Reduce$106.55 - $127.2
($115.78)
$ 101.02-13%Reduce -0.19%29,270
CELGKen Heebner 2015-09-30 Sold Out -0.36%$104.79 - $139.01
($124.1)
$ 101.02-19%Sold Out0
CELGJoel Greenblatt 2015-09-30 Reduce$104.79 - $139.01
($124.1)
$ 101.02-19%Reduce -18.44%6,344
CELGMario Gabelli 2015-09-30 Add$104.79 - $139.01
($124.1)
$ 101.02-19%Add 20.85%29,325
CELGKen Fisher 2015-09-30 Add$104.79 - $139.01
($124.1)
$ 101.02-19%Add 8.99%244,564
CELGRonald Muhlenkamp 2015-06-30 Sold Out -2.08%$107.54 - $120.34
($114.34)
$ 101.02-12%Sold Out0
CELGKen Heebner 2015-06-30 Buy 0.36%$107.54 - $120.34
($114.34)
$ 101.02-12%New holding110,000
CELGJoel Greenblatt 2015-06-30 Reduce-0.01%$107.54 - $120.34
($114.34)
$ 101.02-12%Reduce -56.76%7,778
CELGMario Gabelli 2015-06-30 Reduce$107.54 - $120.34
($114.34)
$ 101.02-12%Reduce -2.71%24,265
CELGKen Fisher 2015-06-30 Reduce$107.54 - $120.34
($114.34)
$ 101.02-12%Reduce -2.40%224,399
CELGRonald Muhlenkamp 2015-03-31 Reduce-0.02%$110.51 - $128.5
($119.49)
$ 101.02-15%Reduce -0.81%85,540
CELGJoel Greenblatt 2015-03-31 Add0.01%$110.51 - $128.5
($119.49)
$ 101.02-15%Add 75.33%17,987
CELGMario Gabelli 2015-03-31 Reduce$110.51 - $128.5
($119.49)
$ 101.02-15%Reduce -0.08%24,940
CELGKen Fisher 2015-03-31 Add$110.51 - $128.5
($119.49)
$ 101.02-15%Add 1.14%229,918
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KAPLAN GILLADirector 2016-04-04Sell15,967$101.84-0.81view
BONNEY MICHAEL WDirector 2016-03-03Buy2,000$103.01-1.93view
LOUGHLIN JAMES JDirector 2016-02-22Sell2,100$104.12-2.98view
MARIO ERNESTDirector 2015-12-28Sell40,000$119.36-15.37view
CASEY MICHAEL DDirector 2015-12-23Sell20,000$122.11-17.27view
KAPLAN GILLADirector 2015-12-21Sell14,464$110.62-8.68view
KAPLAN GILLADirector 2015-09-10Sell15,000$122.45-17.5view
CASEY MICHAEL DDirector 2015-09-08Sell15,000$121.76-17.03view
Daniel Thomas Osee remarks 2015-08-10Sell25,578$130.82-22.78view
MARIO ERNESTDirector 2015-07-31Sell19,442$131.73-23.31view

Press Releases about CELG :

Quarterly/Annual Reports about CELG:

News about CELG:

Articles On GuruFocus.com
DISH Network, H&R Block, Celgene, Plum Creek Timber Log Largest Insider Sells Jan 04 2016 
Taking a Look at Barron’s 10 Favorite Stocks for 2016 Dec 07 2015 
Celgene: A Primer on Growth Stock Value Investing - Part 2 Nov 13 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 
February Pick Of Biotech Stocks Feb 17 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 

More From Other Websites
Biotech: The Next Pricing Controversy? May 23 2016
J&J is Worth as Much as Gilead, Biogen, Mylan, Celgene and Teva Combined. It's Time to Sell. May 20 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences May 20 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences May 20 2016
The top 5 stocks of the past 10 years May 19 2016
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO... May 18 2016
How Revlimid’s Label Expansion Could Boost Celgene’s 2016 Revenue May 18 2016
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO... May 18 2016
Agios shopped new cancer research program around before partnering with Celgene May 18 2016
Agios Strikes Metabolic Immuno-Oncology Deal with Celgene May 18 2016
Celgene Continues Immunology and Inflammation Asset Development May 18 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights... May 17 2016
[$$] Agenovir Targets Viral Infections With $10.6M Series A May 17 2016
Agios Pharmaceuticals Inc Conference Call To Discuss New Metabolic Immuno-Oncology Collaboration... May 17 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights... May 17 2016
Celgene, Agios Expand, Amend Cancer Drug Partnership May 17 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights... May 17 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights... May 17 2016
Celgene Launches Fictional Film, Millefeuille, to Shed New Light on Complex Psoriasis Challenges May 17 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)